Zepbound vs Ozempic: How They Compare

Zepbound and Ozempic differ in active ingredient, drug class, approved use and manufacturer. The table below covers the differences that matter most.

The headline difference in one sentence. Zepbound is a weight management medication. Ozempic is a diabetes medication that also causes weight loss as a secondary effect, and it is not approved for that purpose.

Both carry a boxed warning for the risk of thyroid C-cell tumors, covered in the side effects section below.

Zepbound and Ozempic are approved for different conditions, which makes a direct comparison somewhat mismatched. If your question is really about weight loss, the more directly comparable pairing is Zepbound and Wegovy.

This is not pedantry, and it is not a criticism of the question. The confusion is entirely understandable, because Ozempic became the household name for this class of medication before Wegovy or Zepbound existed.

Most people asking about Ozempic and weight loss are asking a perfectly sensible question using the vocabulary that reached them.

Here is the structure underneath the brand names.

Two molecules. Four brands. Two manufacturers.

Semaglutide is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. Both are made by Novo Nordisk. Same molecule, different maximum doses, different approvals.

Tirzepatide is sold as Mounjaro® for type 2 diabetes and as Zepbound for weight management. Both are made by Eli Lilly. Same molecule, different approvals.

The genuinely like-for-like comparisons are therefore:

• Zepbound vs Wegovy for weight management.
• Mounjaro vs Ozempic for type 2 diabetes.

Meant is not affiliated with, endorsed by, or supplied by Eli Lilly or Novo Nordisk. Brand names are the property of their respective owners.

So why compare Zepbound and Ozempic at all?

Because in practice, this is frequently the real-world choice people face. Insurance may cover one and not the other. A provider may already be prescribing Ozempic for diabetes and the question becomes what else is available. Supply and access differ between products.

The rest of this article gives that comparison honestly, while flagging clearly where the evidence supports a direct comparison and where it does not.

One hard line throughout. Ozempic is not approved by the FDA for weight loss. It is sometimes prescribed off-label for that purpose, meaning outside its approved indication.

Off-label prescribing is legal and common across medicine, but it affects insurance coverage significantly and it means the weight loss evidence for that specific product and dose range is thinner.

Tirzepatide and semaglutide are different molecules that act on different numbers of receptors. That difference is the main reason their results differ.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating, and activates its receptor.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates both the GLP-1 receptor and the receptor for glucose-dependent insulinotropic polypeptide, a second gut hormone.

Those two sentences are the whole mechanistic difference, and everything else follows from them.

What GLP-1 activation does. It stimulates insulin release when blood glucose is high, suppresses glucagon, slows gastric emptying so food stays in the stomach longer, and acts on appetite regulation regions of the brain to increase satiety.

What adding GIP may contribute. This is genuinely less settled, and it is worth being careful here. GIP is also an incretin hormone involved in insulin secretion and fat metabolism.

The authors of the SURMOUNT-5 trial noted that GIP receptors are expressed in brain regions regulating food intake that do not fully overlap with GLP-1 receptor distribution, and hypothesised that this contributes to the greater weight reduction seen with dual agonism in preclinical models.

Note the hedging in that sentence. It is hypothesised, not established. What is established is the outcome difference in trials. The precise mechanism explaining it is still being worked out.

A practical consequence people ask about: both medications have long half-lives supporting weekly dosing. Tirzepatide’s is approximately 5 days. Semaglutide’s is approximately 7 days. Neither difference is clinically significant for weekly dosing, though it slightly affects how quickly each clears if treatment stops.

Tirzepatide has produced greater average weight loss than semaglutide in the one head-to-head trial conducted, but that trial compared Zepbound against Wegovy, not against Ozempic. Understanding what has and has not been directly compared is essential to reading this evidence properly.

SURMOUNT-5 is the only published head-to-head comparison of tirzepatide and semaglutide for weight management. It matters more than any other evidence here, because it is the only trial where both drugs were given to comparable people under the same conditions.

Trial: SURMOUNT-5 (NCT05822830), phase 3b, open-label, randomised, published in the New England Journal of Medicine in 2025. Funded by Eli Lilly.

Population: 751 adults with obesity, or overweight with at least one weight-related complication, without type 2 diabetes. Mean age 44.7 years, 64.7% women, mean BMI 39.4.

Comparison: tirzepatide at maximum tolerated dose (10 mg or 15 mg) versus semaglutide at maximum tolerated dose (1.7 mg or 2.4 mg), once weekly for 72 weeks, alongside a behavioural support programme.

Result: least-squares mean weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide (P<0.001). Mean waist circumference change was −18.4 cm versus −13.0 cm. A weight reduction of at least 30% was achieved by 19.7% on tirzepatide and 6.9% on semaglutide.

Two critical caveats.

First, the semaglutide doses used were Wegovy doses, not Ozempic doses. Semaglutide 1.7 mg and 2.4 mg are Wegovy’s maintenance doses. Ozempic’s maximum is 2 mg. This trial does not tell you how Zepbound compares to Ozempic.

Second, the trial was open-label. Participants and investigators knew which drug was being given, which can influence outcomes and reporting. The authors noted that results were consistent with previously blinded trials, which is reassuring but not equivalent to blinding.

Most comparisons you will read online place figures from separate trials side by side. That is not a valid comparison, and it is worth understanding why before looking at the numbers.

Separate trials enrol different populations, run for different durations, use different dosing schedules and apply different statistical methods.

A 72-week trial in people without diabetes is not comparable to a 40-week trial in people with diabetes, because weight loss is consistently smaller in people with type 2 diabetes.

With that stated, here is what the individual trials found.

SURMOUNT-1 and STEP 1 were separate trials with different designs and durations. Their results are not directly comparable, and the difference between them should not be read as a difference between the drugs. Only SURMOUNT-5 and SURPASS-2 involved direct comparison.

On SURPASS-2 specifically. This 40-week trial compared tirzepatide against semaglutide 1 mg in 1,879 adults with type 2 diabetes taking metformin. Baseline A1C was 8.28%.

At 40 weeks, A1C was 6.42% on semaglutide compared with 6.19%, 5.91% and 5.82% on tirzepatide 5 mg, 10 mg and 15 mg respectively. Tirzepatide 15 mg produced close to twice the weight reduction of semaglutide 1 mg.

One important limitation: 1 mg was the highest approved semaglutide dose for type 2 diabetes when that trial ran. Ozempic is now approved up to 2 mg. SURPASS-2 does not tell us how tirzepatide compares against semaglutide 2 mg.

Average trial results are not predictions about you, and the spread around each average was wide.

In SURMOUNT-1, mean weight reduction on 15 mg was 20.9%. Within that same trial, 91% of participants achieved at least 5% weight reduction, which means roughly 9% did not. Some people lost far more than the average and some lost considerably less.

Response varies for reasons that are not fully understood and cannot currently be predicted before starting. Genetics, baseline metabolic health, other medications, sleep, activity and adherence all contribute.

The honest framing is this: on average, across large trials, tirzepatide produced greater weight reduction than semaglutide. That says something useful about populations and very little about any individual, including you.

Zepbound and Ozempic have broadly similar side effect profiles, dominated by gastrointestinal effects. Both carry the same boxed warning.

Both products carry a boxed warning for the risk of thyroid C-cell tumors. This is the FDA’s most serious warning category and it applies to both.

In rats, both tirzepatide and semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors. Whether either causes thyroid C-cell tumors, including medullary thyroid carcinoma, in humans is unknown, because the human relevance of the rodent findings has not been determined.

Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma, and in people with Multiple Endocrine Neoplasia syndrome type 2.

This is not a footnote. It is a genuine reason some people cannot take either medication, and it is why family history questions appear on every intake form for these drugs.

Both carry warnings covering acute pancreatitis, acute gallbladder disease, acute kidney injury resulting from dehydration, hypoglycemia (particularly alongside insulin or a sulfonylurea), serious hypersensitivity reactions including anaphylaxis and angioedema, and diabetic retinopathy complications in people with type 2 diabetes.

The Zepbound labelling additionally carries warnings on severe gastrointestinal disease and on suicidal behaviour and ideation, advising monitoring for the emergence or worsening of depression or unusual mood changes.

The Ozempic labelling additionally includes a warning on pulmonary aspiration during general anaesthesia or deep sedation, related to delayed gastric emptying. Tell any anaesthetist or surgeon that you take one of these medications well before a procedure.

This is a summary, not a complete list. Read the full prescribing information for whichever product you are considering, and discuss your own risk factors with your prescriber.

Footnote on comparability, and it matters. The Zepbound column shows placebo-controlled trial data from the FDA prescribing information, reported as a range across the 5 mg, 10 mg and 15 mg doses.

The semaglutide column shows SURMOUNT-5 data, where both drugs were given in the same trial and the rates are directly comparable to each other.

Rates from placebo-controlled trials and from active-comparator trials are not interchangeable, which is why the two columns show different figures for Zepbound. Do not read across rows without reading this note.

What the comparable data shows. Within SURMOUNT-5, gastrointestinal side effect rates were broadly similar between the two drugs, with vomiting somewhat more frequent on semaglutide (21.3% versus 15.0%).

Gastrointestinal adverse events causing treatment discontinuation occurred in 2.7% of the tirzepatide group and 5.6% of the semaglutide group.

Practical notes that apply to both. Gastrointestinal effects are most common during dose escalation and typically decrease over time. Both products use gradual dose increases specifically to manage this.

If side effects are severe or persistent, that is a conversation with your prescriber about pace, not a reason to push through.

Our guides cover fatigue and hair loss on tirzepatide in more detail.

Zepbound and Ozempic are both once-weekly subcutaneous injections, but they differ in device format, dose range and titration schedule.

Injection frequency and timing. Both are taken once weekly, on the same day each week, at any time of day, with or without food. Both are injected into the abdomen, thigh or upper arm, rotating sites with each dose.

Device format. This is a real practical difference. Zepbound is supplied in single-dose pens and single-dose vials, each containing one dose that is used and then discarded. Ozempic is supplied in a multi-dose pen containing several doses, with a separate needle attached for each injection.

Dose ranges. Zepbound starts at 2.5 mg weekly and has approved maintenance doses of 5 mg, 10 mg and 15 mg, with a maximum of 15 mg. Ozempic is available in 0.5 mg, 1 mg and 2 mg doses.

Titration. Both escalate gradually to limit gastrointestinal side effects. For Zepbound, the FDA prescribing information specifies 2.5 mg for the first four weeks, then 5 mg, with subsequent increases of 2.5 mg after at least four weeks at the current dose.

Storage. Both require refrigeration, and the details differ by product and format. Single-dose Zepbound pens and vials may be kept at room temperature up to 86°F (30°C) for up to 21 days. Multi-dose pens have different windows.

Our storage guide covers this in detail, and the guidance for one product should never be applied to another.

Practical technique is largely the same across both, and so is how long tirzepatide takes to work once treatment begins. Our injection guide covers sites, rotation and the mistakes that cost part of a dose.

Pricing, coverage and access change frequently. Verify current figures with your insurer and pharmacy.

Cost differences between Zepbound and Ozempic are driven less by list price than by what each product is approved to treat, because approval status determines how insurers handle it.

This section deliberately focuses on the structural factors that change slowly rather than on price points that go stale within months.

Why approval status drives coverage. Insurers generally cover medications for their FDA-approved indications. Ozempic is approved for type 2 diabetes, so coverage for a person with type 2 diabetes is relatively common.

Ozempic is not approved for weight loss, so coverage for that purpose is frequently denied.

Zepbound is approved for chronic weight management, which removes the off-label problem. It introduces a different one: many US insurance plans exclude weight loss medications as a category, regardless of approval status. Medicare has historically been restricted in covering medications prescribed for weight loss specifically.

The result is a situation many people find genuinely confusing. A medication can be approved for exactly what you want it for and still not be covered, while a medication that is not approved for it is covered for someone else with a different diagnosis.

Prior authorisation. Both products commonly require prior authorisation, meaning your prescriber must submit clinical documentation before the insurer agrees to pay. Requirements vary by plan and typically involve documenting BMI, weight-related conditions, and sometimes prior attempts at weight management.

Prior authorisation is a paperwork process, not a judgement on whether you need the medication. Denials can often be appealed, and appeals succeed more often than people expect.

Manufacturer savings programs. Both Eli Lilly and Novo Nordisk operate savings programs for their products. Eligibility rules differ, commonly depending on insurance status, and terms change. Check the manufacturer’s own website for current terms rather than relying on any third-party summary, including this one.

Compounded alternatives. Compounded versions of these medications are prepared by compounding pharmacies rather than the original manufacturers. Regulatory status in this area has shifted repeatedly and continues to change.

If considering a compounded product, ask specifically about the pharmacy’s licensing, what documentation comes with the product, and what its storage instructions are.

Nothing here is a statement about what you will pay. Actual cost depends on your insurance, your plan’s formulary, your deductible, your pharmacy and any savings program you qualify for. The only reliable way to find out is to ask your insurer and pharmacy directly.

Four brand names, two molecules and two manufacturers is the source of nearly all confusion in this category. This table resolves it.

Which comparison makes sense for you?

• If weight management is your goal: Zepbound and Wegovy are the two approved options, and SURMOUNT-5 directly compared them.
• If type 2 diabetes management is your goal: Mounjaro and Ozempic are the relevant pair, and SURPASS-2 compared tirzepatide against semaglutide 1 mg in that population.
• If you have both: all four become potentially relevant, and the decision depends heavily on your specific clinical picture and insurance.
• If cardiovascular or kidney disease is a factor: approval differences matter considerably here. Wegovy and Ozempic carry specific cardiovascular indications, and Ozempic carries a chronic kidney disease indication.

A note on Wegovy and Ozempic being the same molecule. They are. The differences are maximum dose, approved indication and pricing. This is why people sometimes ask whether they can simply take a higher dose of Ozempic instead of Wegovy.

That is a prescribing decision, it constitutes off-label use, and it affects insurance coverage. Raise it with your prescriber rather than acting on it.

One recent source of additional confusion. In February 2026 the FDA approved the Ozempic name for oral semaglutide tablet formulations for type 2 diabetes, previously marketed under a different brand name. If you encounter references to Ozempic tablets, that is what is being described.

Injectable and oral formulations are not interchangeable.

Which medication suits you depends on your diagnosis, your other health conditions, your insurance and your prescriber’s clinical judgement. This table frames scenarios worth discussing rather than recommendations.

Language matters here, so to be explicit: every row above describes something worth discussing, not something you should take. Only a prescriber who knows your full history can make that call.

Questions worth bringing to that appointment:

• Which of these am I actually a candidate for, given my history?
• Which does my insurance cover, and what does prior authorisation require?
• What would we do if I do not tolerate the first choice?
• How will we assess whether it is working, and when?
• What happens if I need to stop?

The choice of molecule matters less than what happens after. Dose pace, side effect management, protein adequacy and technique determine most of the difference between a good outcome and a frustrating one. That is the part a prescription alone does not cover.

Switching between these medications is possible and happens routinely, always under clinical supervision. It is not something to attempt independently.

Why people switch. Common reasons include insurance coverage changing, supply availability, side effects that do not settle, results falling short of expectations, or a change in diagnosis such as developing type 2 diabetes.

What switching involves. These are different molecules with different dose scales, so doses do not translate across. There is no conversion between a semaglutide dose and a tirzepatide dose.

In practice, switching generally means starting the new medication at its own starting dose and titrating up from there, rather than beginning at an equivalent of your previous dose.

Your prescriber determines the specifics, including any gap between the last dose of one and the first dose of the other.

What to expect. Titration restarting means gastrointestinal side effects may return during the escalation period, even if you had settled on your previous medication. Appetite suppression may feel different in character, not only in strength.

Weight loss frequently slows or stalls temporarily during a switch, because the new medication is at a starting dose. This is expected and is not evidence the new medication is not working. Our guide to stalled weight loss covers how to read that period.

Do not attempt this yourself. Do not overlap the two medications. According to the FDA prescribing information for Zepbound, coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Do not calculate your own equivalent dose.

Every aspect of a switch goes through your prescriber.

Most comparison articles end at the comparison, as though the decision were the hard part.

It usually is not.

The harder part is everything after: getting through titration without abandoning treatment, managing side effects that peak in the first weeks, keeping protein adequate when appetite disappears, handling the plateau that arrives around month nine, and knowing whether a stall means the dose, the technique or something else entirely.

That is what supervised care covers. Dose reviewed against your response rather than a schedule. Side effects addressed as they emerge. Storage and technique checked before anyone reaches for a dose increase.

Whichever medication you and your prescriber choose, the support around it determines a great deal.